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Introduction 
Epidermotropic B-cell lymphoma (EBCL) is a very rare 
form of cutaneous marginal zone lymphoma (MZL) 
with a distinctive clinical and histopathologic 
presentation. This diagnosis is rarely suspected 
clinically and therefore familiarity with this 
lymphoma is imperative to allow critical and correct 
therapeutic interventions. Although there can be 
extensive clinical disease including bone marrow 
and spleen involvement, the prognosis appears 
favorable. As opposed to the other forms of 
cutaneous B cell lymphoma, which usually present 
with a solitary or few plaques and nodules, this 
particular form of MZL characteristically manifests in 
the skin as widespread papules and plaques with the 
individual lesions described as salmon-colored, 
resulting in a presentation that can simulate a 
reactive papulosquamous eruption [1, 2]. The 
eruption bears a strong clinical resemblance with 
pityriasis rosea. In at least one reported case the 
lymphoma was likely disseminating from the spleen 
[3], whereas in the other cases the skin involvement 
presaged any extracutaneous dissemination. 
However, it was established that there was spleen 
involvement in four of the cases, and bone marrow 
involvement in four of the cases at the time that the 
diagnosis was first made of epidermotropic MZL. In 
these cases the skin eruption had been present for a 
period of time ranging from months-to-years prior to 
a definitive diagnosis of epidermotropic B cell 
lymphoma. In three of the 8 cases the spleen and 
Abstract 
Epidermotropic B cell lymphoma represents a rare 
form of marginal zone lymphoma presenting as a 
disseminated skin rash resembling pityriasis rosea. To 
date there are 8 reported cases. In addition to the 
widespread nature of the skin rash, there is a 
proclivity for spleen and bone marrow involvement 
raising consideration regarding its categorization as 
a systemic lymphoma. We present an 89-year-old 
man with epidermotropic B cell lymphoma, who 
presented with a pityriasis rosea-like skin rash.  An 
initial diagnosis of diffuse large cell B cell lymphoma 
was made based on the extent of dermal-based large 
cell infiltration. However, after recognizing the 
epidermotropic component and the distinctive 
clinical presentation, a diagnosis of epidermotropic B 
cell lymphoma was rendered. There was minimal 
bone marrow involvement based only on flow 
cytometric analysis, but there was no apparent bone 
marrow or splenic involvement on routine light 
microscopic assessment. Remission was achieved 
with single agent rituximab chemotherapy and the 
patient remained symptom free. The neoplastic 
CD20 positive epidermotropic B lymphocytes 
expressed CXCR3. Similar to the prior reported cases 
by the authors, the neoplastic cells expressed CXCR3, 
a chemokine whose organ and tissue specific ligands 
could contribute to its relatively indolent clinical 
course. 
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bone marrow involvement was concurrent [1, 2, 4-9]. 
A summary of these cases is presented in Table 1. 
Epidermotropism, the abnormal migration of 
leukocytes into epithelial structures, is characteristic 
of cutaneous T-cell lymphoma (CTCL). The spectrum 
of epidermotropic disorders includes mycosis 
fungoides (MF), Sezary syndrome, Woringer-Kolopp 
disease, aggressive CD8+ epidermotropic T-cell 
lymphoma, gamma/delta T-cell lymphoma, 
lymphomatoid papulosis types B and D, and 
Langerhans cell histiocytosis [10]. Epidermotropism 
is not a feature of B cell lymphoma in general and 
when one encounters a CD20+ epidermotropic 
lymphocytic infiltrate, CD20+ mycosis fungoides 
becomes an important diagnostic consideration [11]. 
It is likely that certain acquired functional 
characteristics of neoplastic B cells, mirroring those 
seen in MF, could account for the epidermotropism. 
Although our case showed a conspicuous large cell 
infiltrate in the dermis, the epitheliotropic B cell 
populace was in the context of small atypical 
somewhat monocytoid appearing cells tagging 
along the dermoepidermal junction. A similar 
pattern of small cell lymphocytic infiltration of the 
epidermis as opposed to the larger lymphoid dermal 
populace was also observed in the prior cases 
presented by the authors [1, 2]. The parallel would be 
MF in which the epidermotropic cell populace 
typically comprises smaller lymphocytes, whereas in 
disease progression, tumor progression and or large 
cell transformation, a lack of epidermotopism occurs 
[12]. 
It has been previously hypothesized that there is a 
specific epidermal chemoattractant in neoplastic B 
cells, namely the chemokine receptor CXCR3. CXCR3 
expression by neoplastic T cells in the setting of 
mycosis fungoides has been postulated as the basis 
of the epidermotropism [1]. The natural ligands for 
CXCR3 include interferon gamma-induced protein 
10 and P-9/I-TAC (interferon-inducible T-cell alpha 
chemoattractant) found within the keratinocytes. 
Interferon γ–induced protein 10 is also expressed by 
stromal cells of the spleen and bone marrow, 
potentially accounting for the significant risk of 
splenic and bone marrow involvement in this rare 
form of cutaneous B cell lymphoma. Given the 
Table 1. Cases of generalized Epidermotropic B Cell Lymphoma presenting initially in the skin. 
Case Ref. Age Sex 
Skin 
Manifestation 
Bone Marrow 
Involvement 
Peripheral 
Blood 
Involvement 
Spleen 
Involvement 
Treatment/ 
Outcome 
Chui et al. [9] 70 M Abrupt PGSR + 7 months - - Chemotherapy/ 
remission
Pavlović et al. [7] 56 M 1.5 ys W/W PGSR - - - Phototherapy/ 
remission
Chiang et al. [6] 57 M 5 year PGSR + 5 years + 5 years + 5 years Phototherapy/ 
remission
Gómez-de la 
Fuente et al. [5] 68 M 1 year GSR + 1 year + 1 year + 1 year 
Splenectomy & 
chemotherapy/ 
died from 
hepatitis 
Lee et al. [4] 80 M 2 weeks PGSR N/A N/A N/A N/A
Magro et al. [2] 51 M 7 months GSR + 7 months - - Chemotherapy/ remission
Magro et al. [1] 69 M 6 Months GSR - - 6 Months 
Rituximab/ 
remission with 
decrease in 
spleen size
Hedayat et al. [8] 66 F 12 years w/w GSR + 12 years + 12 years + 12 years None 
Current case 89 M AGSR + BM flowcytometry - - 
Rituximab 
/remission 
Abbreviations: PGSR: Pruritic generalized skin rash; W/W: waxing and waning; GSR: Generalized skin rash; N/A: Not available; AGSR: 
Asymptomatic generalized skin rash 
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frequency of extracutaneous disease, one could 
argue that epidermotropic MZL is a systemic 
lymphoma that has unique homing properties 
largely limiting its anatomic distribution to the skin, 
bone marrow, and spleen [13], organs in which there 
is expression of interferon γ-induced protein 10. We 
describe the ninth case, to our knowledge, of 
multifocal epidermotropic marginal zone 
lymphoma. 
 
Case Presentation 
A previously healthy 89-year-old man presented 
with an abrupt onset of an asymptomatic skin 
eruption. It started three weeks earlier on the chest 
and spread to the proximal extremities and face with 
a daily increase in number and size of lesions. He had 
no constitutional symptoms. 
On physical examination there were multiple non-
scaly, oval and dome-shaped red papules and 
plaques ranging in size from 1-2.5cm on his chest, 
abdomen, back, face, arms, legs, palms, and soles, 
manifesting a pityriasis rosea-like distribution 
(Figure 1A, B). A purple plum-like nodule was also 
present on the left wrist (Figure 1C). There were no 
mucosal lesions or lymphadenopathy. Over the two 
weeks between the first and second skin biopsies he 
started to develop leonine facies. 
The patient had two sets of biopsies with similar 
findings. In both, there was an extensive 
multinodular lymphocytic infiltrate spanning the 
entire dermis, exhibiting a rather orderly disposition 
around nerves, blood vessels, and the eccrine coils 
(Figure 2A). The typical syringoepithelial 
hyperplasia characteristic of syringotropic MF was 
not seen. Many of the dermal lymphocytes were in 
the 15-20μm size range exceeding the size of the 
intraepidermal lymphocytes (Figure 2B, C). The 
nuclei were round-to-oval and reniform in shape, 
exhibiting a variable disposition in the cell, including 
an eccentrically disposed nucleus resulting in a 
monocytoid quality. The cytoplasm was abundant 
and lightly eosinophilic. There was a significant 
degree of histiocytic infiltration resulting in a distinct 
granulomatous quality to the infiltrate (Figure 2D). 
In all biopsies there was a variable interface 
dermatitis associated with some degree of vacuolar 
alteration of the papillary dermis. The lymphocytes 
infiltrating the epidermis were small-to-intermediate 
in size revealing some degree of nuclear contour 
irregularity, although a cerebriform appearance was 
not observed (Figure 2E). Large neoplastic cells 
permeating the epidermis were also not present. The 
intraepidermal and intrafollicular epithelial 
lymphocytic infiltrate, as well as the dermal 
component including the larger atypical cells were 
highlighted in part by CD20 and CD79a (Figure 3A). 
Extensive expression of BCL2 and IgG was also noted. 
A significant degree of T cell hyperplasia was seen as 
characterized by the extent of immunoreactivity of 
the infiltrate for CD3. The atypical B cell infiltrate was 
highlighted by CXCR3 (Figure 3B). The neoplastic 
cells were negative for CD56, CD10, CD30, EBV-
encoded RNA (EBER), cyclin-D1, and p16. The Ki-67 
proliferation index was higher in the areas of large 
cell infiltration with an overall 30%-50% proliferation 
index. MUM1 preparation highlighted the neoplastic 
large cells. 
Fluorescence in situ hybridization on paraffin section 
slides were negative for c-Myc, IGH-BCL2 gene 
Figure 1. A) The patient developed multiple red papules and oval dome-shaped plaques ranging in size from 1-to-2.5cm. B) The plaques 
exhibited a pityriasis rosea-like distribution. C)There was a purple plum-like nodule on the left wrist. 
A B C
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rearrangement, and CDKN2A (p16) deletion. 
Immunoglobulin heavy chain studies revealed B cell 
clonality. 
Subsequent analysis that was conducted on a bone 
marrow sample disclosed a small lambda light chain 
restricted lymphocytic infiltrate representing less 
than 0.85% of all cells analyzed by flow cytometry. 
These cells also expressed dim CD23. In addition, 
there was a small population of kappa light chain 
restricted CD38+ CD138+ B cells defining less than 
0.01% of all cells present. Although flow cytometry 
detected this abnormal cell population, routine light 
microscopic assessment of the bone marrow sample 
did not demonstrate any evidence of lymphoma. 
There was no evidence of spleen involvement either 
on clinical examination or radiographic studies. 
The rapid progression of the skin eruption was 
associated with facial swelling and prompted a 
course of prednisone 80mg/day for one week before 
the first course of chemotherapy with CHOP 
(cyclophosphamide, doxorubicin, vincristine, and 
prednisolone) was initiated based on the initial 
diagnosis of a diffuse large cell B cell lymphoma 
(DLBCL). Subsequent to the revised pathologic 
diagnosis of EBCL, treatment was changed to 
rituximab infusions alone, which produced clearing 
 
Figure 2. A) Low-power magnification shows a multinodular infiltrate that spanned the entire dermis exhibiting an orderly disposition 
around nerves, blood vessels, and the eccrine coil. H&E, 20×. B) Many of the dermal lymphocytes were in the 15-20μm size range 
exceeding the size of the intraepidermal lymphocytes. H&E, 200×, C) H&E, 400×. D) There was a significant degree of histiocytic 
infiltration resulting in a distinct granulomatous quality to the infiltrate. H&E, 200×. E) The lymphocytes infiltrating the epidermis were 
small to intermediate in size showing some degree of nuclear contour irregularity, however, cells with a cerebriform appearance were 
not identified. H&E, 400×; Illustration reveals average density of epidermotropism. 
A B C 
D E 
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of his skin rash. On follow-up, the patie  nt is currently 
disease free without any symptoms. 
 
Discussion 
The distinctive clinical presentation along with the 
histomorphology and immunophenotypic profile 
was diagnostic of a very rare form of B cell 
lymphoma, namely epidermotropic B-cell 
lymphoma. It is held to represent an unusual variant 
of MZL and in this case one might propose the 
designation of primary cutaneous epidermotropic 
MZL. In particular the skin involvement occurred 
initially and subsequent staging did not reveal frank 
lymphomatous infiltration of other organ sites, 
although small kappa and lambda light chain 
restricted B cell populations were identified by flow 
cytometry despite the lack of any light microscopic 
evidence of neoplastic B cell infiltration within the 
bone marrow [1]. 
The first reported case of epidermotropic B cell 
lymphoma was in 1999 by Chui and co-workers; they 
described a 70-year-old man who presented with a 
mildly pruritic rash involving the trunk and proximal 
extremities of 7-months duration [9]. The eruption 
was initially considered a presentation of MF. 
However, findings of a subsequent work up 
including a bone marrow biopsy was compatible 
with an extranodal MZL associated with an 
exceptionally uncommon finding of significant B cell 
epidermotropism neoplasia; the patient underwent 
chemotherapy. 
This case would make the ninth reported case of 
primary cutaneous epidermotropic B cell lymphoma, 
to our knowledge. A summary of all known cases 
with generalized cutaneous epidermotropic B cell 
lymphoma presenting in the skin is presented in 
Table 1. In general, this unusual variant of B cell 
lymphoma exhibits a reproducible presentation 
from a clinical perspective, although the 
pathological picture is somewhat variable. Clinically, 
epidermotropic B-cell lymphoma has a characteristic 
presentation in elderly men (ages range from 51-89 
years old, mean age 64, male to female 8:1). Patients 
are generally healthy without B symptoms (fever, 
weight loss, night sweats, or malaise) and present 
with an abrupt onset of unexplained and mostly 
asymptomatic (5/9 asymptomatic, 4/9 pruritic) 
disseminated skin rash. The dull red papules and 
plaques at first examination may appear in a 
pityriasis rosea-like distribution. On closer 
inspection, the lesions are dome-shaped and non-
scaly. The lesions involve areas that are typically not 
involved by pityriasis rosea including the palms, 
soles, face, and distal extremities. 
Lymphadenopathy, hepatomegaly or mucosal 
involvement are typically absent. However, bone 
marrow and splenic involvement are quite common 
 
Figure 3. The intraepidermal and intrafollicular epithelial lymphocytic infiltrate was highlighted in part by CD20 and CD79a and as well, 
much of the dermal component including the larger atypical cells were positive for CD20 and CD79a. A) CD79a immunohistochemistry, 
200×. B) The atypical B cell infiltrate are also highlighted by CXCR3 immunohistochemical staining, 1000×. 
A B
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[1-9]. Bone marrow involvement occurred in 6 of the 
9 cases whereas spleen involvement occurred in 4 of 
the 9 cases, with 3 of the 9 cases having concurrent 
spleen and bone marrow involvement. In our patient 
there was evidence of minimal bone marrow 
involvement, although only based on flow 
cytometric analysis, which demonstrated small 
kappa and small lambda light chain restricted 
infiltrates; there was no evidence of spleen 
involvement.  
Given the initial presentation with skin eruption for a 
period of at least a few months-to-years that 
presaged any known extracutaneous involvement, 
one could make the argument that such cases 
represent forms of primary cutaneous 
epidermotropic MZL. However, once the diagnosis 
was made of epidermotropic MZL, extracutaneous 
involvement of these other extracutaneous organ 
sites was established in 4 of the 9 cases. In this regard 
it is impossible to know if the bone marrow, blood, 
and spleen involvement had developed first before 
the skin manifestations became apparent. Hedayat 
and co-workers indicated that despite an initial 
presentation in the skin for years, the lymphoma was 
a splenic MZL secondarily involving the skin [8]. The 
predilection for involvement of the spleen and bone 
marrow presumably is reflective of the natural 
homing tendency of this unique form of lymphoma. 
It is well established that primary forms of cutaneous 
lymphoma can exhibit  
extracutaneous spread to other organ sites. In a 
recent letter to the editor by Baykal and co-workers 
[3], the authors described a case that exactly 
recapitulates cases of cutaneous epidermotropic 
MZL, clinically and histologically first presenting in 
the skin. The patient, however, had an established 
history of splenic MZL and then developed a relapse 
in the skin four years subsequent to the initial 
diagnosis of splenic MZL. Although in this particular 
case, features that are considered unusual for a 
diagnosis of a primary splenic MZL include the lack 
of the distinctive villous cytomorphology and the 
absence of expression of IgD by the neoplastic cells 
[3]. It may be impossible to definitively classify cases 
that have concomitant bone marrow and or spleen 
involvement at the time of initial diagnosis in the skin 
as forms of primary cutaneous marginal zone 
lymphoma. However, there are clearly cases in which 
the only affected organ is the skin, although they are 
indistinguishable from cases with multiorgan 
involvement. There is at least one case in which the 
initial systemic evaluation following the skin 
diagnosis was without bone marrow and spleen 
involvement. However, several months later the 
patient developed lymphomatous infiltration of the 
bone marrow [2]. 
It is likely that the critical receptor ligand interactions 
that result in the PR-like disseminated cutaneous 
form of MZL also lead to bone marrow and spleen 
involvement. Perhaps one might consider 
epidermotropic MZL as a unique skin lymphoma 
with frequent spleen and bone marrow involvement 
and that may be indeterminate with regard to the 
initial site of involvement. We have observed cases 
without documentation of spleen involvement, 
including the current case, indistinguishable from 
those cases with spleen involvement.  
This case exhibited pathological features that have 
been encountered in other cases of epidermotropic 
B cell lymphoma. Although the three cases we 
encountered in our previously published studies had 
large cell infiltration [1, 2], the other three published 
cases that we reviewed showed a neoplastic B cell 
population that was predominated by small B cells 
[2]. 
In this case the striking angiotropism, perieccrine 
accentuation, and perineural infiltration was similar 
to that seen in our previously examined cases [1, 2]. 
This pattern of perineural infiltration and 
angioinvasion of B cells accompanied by a 
background reactive T cell infiltrate was highly 
reminiscent of lymphomatoid granulomatosis. What 
is not supportive of this diagnosis was the lack of 
EBER staining amidst the B cells over and above the 
unusual epidermotropic epidermal changes. In 
addition, the distinctive pityriasis rosea-like skin rash 
to date has not been described in the spectrum of 
lymphomatoid granulomatosis. In this case as well as 
others, the phenotypic profile did not support a 
germinal center origin as the cells were BCL6 and 
CD10 negative [14]. 
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Although this case was initially interpreted as a 
DLBCL, the distinctive clinical presentation with a 
disseminated skin rash resembling pityriasis rosea 
was unusual for DLBCL. In addition, the orderly 
multinodular non-effacing growth pattern around 
nerves, blood vessels, and the eccrine coil without 
diffuse infiltration and the presence of 
epidermotropism, which has been only rarely 
reported in DLBCL, were not compatible with DLBCL 
[15, 16]. Moreover, there were many admixed smaller 
neoplastic B cells. The overall phenotypic profile 
along with expression of IgG, that implied an isolated 
switched neoplastic B cell of post germinal center 
origin, was not typical for DLBCL. The tendency for 
the neoplastic cells to gather around pre-existing 
cutaneous dermal structures produced a picture that 
architecturally mimicked a reactive inflammatory 
dermatosis. However, there should be no confusion 
with a reactive process since the cytologies of the  
lymphocytes were clearly in the context of a 
malignant lymphoma. 
The unique homing of the neoplastic cells to 
epithelial structures, nerves, and blood vessels could 
also potentially be explained by a ligand receptor 
interaction. We already demonstrated a prominent 
pattern of CXCR3 staining amidst the neoplastic B 
cells in this case and other similar previously 
reported cases. The ligand is naturally found in 
keratinocytes but additional ligand sources would 
also include endothelium and stromal cells found in 
the spleen and bone marrow, which might account 
for the angiotropic properties of the infiltrate. A 
similar pattern of controlled selective migration of 
neoplastic T cells is best exemplified by MF, in which 
there is a critical interplay between the T cell and the 
intraepidermal microenvironment. 
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